These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 21672014)

  • 21. Mucopolysaccharidosis type II, Hunter's syndrome.
    Tylki-Szymańska A
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of recombinant human iduronate-2-sulfatase (Idursulfase) on growth in young patients with mucopolysaccharidosis type II.
    Żuber Z; Różdżyńska-Świątkowska A; Jurecka A; Tylki-Szymańska A
    PLoS One; 2014; 9(1):e85074. PubMed ID: 24454794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA damage in leukocytes from pretreatment mucopolysaccharidosis type II patients; protective effect of enzyme replacement therapy.
    Filippon L; Wayhs CA; Atik DM; Manfredini V; Herber S; Carvalho CG; Schwartz IV; Giugliani R; Vargas CR
    Mutat Res; 2011 Apr; 721(2):206-10. PubMed ID: 21334454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
    Kim J; Park MR; Kim DS; Lee JO; Maeng SH; Cho SY; Han Y; Ahn K; Jin DK
    Allergy; 2013 Jun; 68(6):796-802. PubMed ID: 23621439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
    Pano A; Barbier AJ; Bielefeld B; Whiteman DA; Amato DA
    Orphanet J Rare Dis; 2015 Apr; 10():50. PubMed ID: 25902842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glycosaminoglycans can be associated with oxidative damage in mucopolysaccharidosis II patients submitted to enzyme replacement therapy.
    Negretto GW; Deon M; Biancini GB; Burin MG; Giugliani R; Vargas CR
    Cell Biol Toxicol; 2014 Aug; 30(4):189-93. PubMed ID: 25022704
    [No Abstract]   [Full Text] [Related]  

  • 28. Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.
    Prescrire Int; 2008 Jun; 17(95):109. PubMed ID: 18630351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome).
    Sohn YB; Cho SY; Park SW; Kim SJ; Ko AR; Kwon EK; Han SJ; Jin DK
    Orphanet J Rare Dis; 2013 Mar; 8():42. PubMed ID: 23497636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (Hunter syndrome).
    Serrano CD; Gomez JF
    J Investig Allergol Clin Immunol; 2011; 21(7):571-2. PubMed ID: 22312944
    [No Abstract]   [Full Text] [Related]  

  • 31. Parental experience of enzyme replacement therapy for Hunter syndrome.
    Buraczewska M; O'Leary D; Walsh O; Monavari A; Crushell E
    Ir Med J; 2013 Apr; 106(4):120-2. PubMed ID: 23691848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS).
    Muenzer J; Giugliani R; Scarpa M; Tylki-Szymańska A; Jego V; Beck M
    Orphanet J Rare Dis; 2017 Oct; 12(1):161. PubMed ID: 28974237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in an attenuated case of mucopolysaccharidosis type I (Scheie syndrome): a 6.5-year detailed follow-up.
    Jurecka A; Marucha J; Jurkiewicz E; Różdżyńska-Świątkowska A; Tylki-Szymańska A
    Pediatr Neurol; 2012 Dec; 47(6):461-5. PubMed ID: 23127271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative stress in patients with mucopolysaccharidosis type II before and during enzyme replacement therapy.
    Filippon L; Vanzin CS; Biancini GB; Pereira IN; Manfredini V; Sitta A; Peralba Mdo C; Schwartz IV; Giugliani R; Vargas CR
    Mol Genet Metab; 2011 Jun; 103(2):121-7. PubMed ID: 21420339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of enzyme replacement therapy in paediatric Hunter patients, an independent study of 3.5 years.
    Tomanin R; Zanetti A; D'Avanzo F; Rampazzo A; Gasparotto N; Parini R; Pascarella A; Concolino D; Procopio E; Fiumara A; Borgo A; Frigo AC; Scarpa M
    Orphanet J Rare Dis; 2014 Sep; 9():129. PubMed ID: 25231261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
    Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
    Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
    Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
    Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature.
    Jurecka A; Żuberuber Z; Opoka-Winiarska V; Węgrzyn G; Tylki-Szymańska A
    Mol Genet Metab; 2012 Nov; 107(3):508-12. PubMed ID: 22926198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
    Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
    Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).
    Burton BK; Jego V; Mikl J; Jones SA
    J Inherit Metab Dis; 2017 Nov; 40(6):867-874. PubMed ID: 28887757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.